Today Janssen Products, LP announced that it has restored full access to Doxil® (doxorubicin HCl liposome injection) supply for physicians and their patients in the United States. Janssen also announced that it has suspended its Doxil® C.A.R.E.S. Physician Access Program, since this drug is no longer in shortage.
“This is encouraging news for women with ovarian cancer and their health providers,” said Calaneet Balas, Chief Executive Officer of the Ovarian Cancer National Alliance. “We are relieved to know that Doxil will now be available to all patients as a treatment for ovarian cancer.”
Throughout the past year, the Alliance has worked with stakeholders—including FDA and the drug industry—to resolve current drug shortages and prevent future problems. We will continue to update our website with additional information about drug shortages as it is available. Patients who have been affected by drug shortages can share their personal stories through our dedicated website, www.StopDrugShortages.org.
Physicians can begin placing Doxil orders through their normal distribution channels starting on October 22, 2012. For a list of approved distributors, visit www.jom.com/products.html and select Doxil. More details and direction for these physicians can be found in the Dear Healthcare Professional Letter on DOXIL.com.